Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,496,316 on Dec. 17, 2025 for methods of administering isolated allogeneic mesenchymal stem cells (MSCs) to treat female sexual dysfunction and improve sexual quality of life.
The patent provides U.S. rights through 2038 with potential patent term or regulatory exclusivity extensions. The company noted female sexual dysfunction affects up to 46% of women and said the patent expands its aging-focused intellectual property portfolio. Longeveron anticipates pursuing licensing or partnering opportunities for development and commercialization of the therapy.
Positive
- U.S. Patent No. 12,496,316 granted (effective Dec. 17, 2025)
- Patent protection in the U.S. through 2038
- Company intends to pursue licensing or partnering for commercialization
Negative
- None.
News Market Reaction 7 Alerts
On the day this news was published, LGVN gained 7.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.4% during that session. Argus tracked a trough of -10.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $921K to the company's valuation, bringing the market cap to $13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LGVN was up 0.45% while peers showed mixed moves: NBY up 16.18%, EDSA up 1.71%, MTVA down 1.21%, PULM down 5.53%, SYBX down 0.93%, indicating stock-specific drivers rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Conference participation | Positive | -1.2% | Executives featured as speakers on cell therapy topics at CVCT Forum. |
| Dec 02 | Patent grant | Positive | +2.2% | Canadian patent for MSC therapy in NIDCM and aging-related frailty. |
| Dec 01 | Clinical data update | Positive | -5.1% | Phase 2 MRI biomarker data in mild Alzheimer’s presented at CTAD 2025. |
| Nov 19 | Conference poster | Positive | -4.0% | Laromestrocel Alzheimer’s poster selected for CTAD 2025 presentation. |
| Nov 12 | Patent grant | Positive | -1.3% | U.S. patent on treating aging-related frailty with inflammaging using MSCs. |
Recent positive clinical and patent news often coincided with negative price reactions, with only one of five events showing an aligned positive move.
Over the past month, Longeveron has focused on expanding its intellectual property and clinical visibility. U.S. and Canadian patents through 2037–2038 for inflammaging-related frailty and cardiomyopathy strengthened protection around its mesenchymal stem cell platform. Concurrently, Alzheimer’s data from the CLEAR MIND Phase 2 study were highlighted at CTAD 2025, alongside poster and speaking engagements. Despite these milestones, shares frequently traded lower after news. Today’s U.S. patent for treating female sexual dysfunction extends this IP-building trend into a new indication.
Market Pulse Summary
The stock moved +7.8% in the session following this news. A strong positive reaction aligns with the strategically important U.S. patent extending protection through 2038 for a new indication in female sexual dysfunction. However, historical data show that four of the last five largely positive announcements were followed by negative price moves. Combined with shrinking revenue and wider losses from Q3 2025 filings, investors would have needed to consider balance-sheet risk when assessing the durability of any sharp upside move.
Key Terms
allogeneic medical
mesenchymal stem cells medical
female sexual dysfunction medical
United States Patent and Trademark Office (USPTO) regulatory
patent term extension regulatory
regulatory exclusivity regulatory
AI-generated analysis. Not financial advice.
- The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of life
- Female sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy women
- Longeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication
MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent covering administration of the Company’s proprietary mesenchymal stem cells (MSCs) for the treatment of female patients with sexual dysfunction and improvement in sexual quality of life.
U.S. Patent No. 12,496,316, entitled “Treatment of Sexual Dysfunction and Improvement in Sexual Quality of Life,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.
Female sexual dysfunction is an extremely common yet under-researched issue affecting up to
Longeveron anticipates entering into licensing or partnering agreements for the potential development and commercialization of stem cell therapy for this indication.
About laromestrocel (LOMECEL-B®)
Laromestrocel is a living cell product made from specialized cells isolated from the bone marrow of young healthy adult donors. These specialized cells, known as mesenchymal stem cells (MSCs), are essential to our endogenous biological repair mechanism. MSCs have been shown to perform a number of complex functions in the body, including the formation of new tissue. They also have been shown to respond to sites of injury or disease and secrete bioactive factors that are immunomodulatory and regenerative. We believe that laromestrocel may have multiple potential mechanisms of action that may lead to anti-inflammatory, pro-vascular regenerative responses, and therefore may have broad application for a range of rare and aging related diseases.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (LOMECEL-B®), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Pediatric Dilated Cardiomyopathy (DCM). Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain and maintain regulatory approval of our product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.
Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
What did Longeveron announce on Dec. 17, 2025 regarding LGVN?
How long does the Longeveron patent for female sexual dysfunction protect LGVN's therapy?
What therapy does the LGVN patent cover for female sexual dysfunction?
Does Longeveron plan to commercialize the LGVN stem cell therapy directly?
How prevalent is female sexual dysfunction cited in the LGVN announcement?
Will the LGVN patent affect the company’s existing intellectual property portfolio?
